SAN DIEGO, CA, USA I October 10, 2013 I Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has acquired Sherrington Pharmaceuticals, Inc. (Sherrington), a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications.
Sherrington’s drug candidate, known as Resiniferatoxin, is a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor. A single injection of the compound is expected to permanently block the transmission of pain signals without impairing the mental or physical faculties of the patient, common side effects of opiate treatment. Resiniferatoxin was recently highlighted in the July 2013 issue of Scientific American1. Resiniferatoxin is currently in an investigator-sponsored Phase 1/2 clinical trial at the National Institutes of Health (NIH) under a company sponsored Collaborative Research and Development Agreement (CRADA). Sorrento plans to initiate additional clinical studies to rapidly advance the drug.
“Sorrento’s drug development pipeline now includes an additional clinical stage program to go along with its late stage program Cynviloq™ and robust pipeline of fully human therapeutic antibodies,” said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. “Resiniferatoxin is a great fit with our mission to treat cancer patients with targeted and selective treatments. End-stage cancer pain is a particularly high unmet medical need and the early data with Resiniferatoxin are very encouraging.”
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento’s therapeutic focus is oncology, but it is also developing therapeutic products for inflammation, metabolic, and infectious diseases. Sorrento’s proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary ADCs as well as AfDCs combining its G-MAB® antibodies with anti-tumor agents.
SOURCE: Sorrento Therapeutics
Post Views: 229
SAN DIEGO, CA, USA I October 10, 2013 I Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has acquired Sherrington Pharmaceuticals, Inc. (Sherrington), a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications.
Sherrington’s drug candidate, known as Resiniferatoxin, is a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor. A single injection of the compound is expected to permanently block the transmission of pain signals without impairing the mental or physical faculties of the patient, common side effects of opiate treatment. Resiniferatoxin was recently highlighted in the July 2013 issue of Scientific American1. Resiniferatoxin is currently in an investigator-sponsored Phase 1/2 clinical trial at the National Institutes of Health (NIH) under a company sponsored Collaborative Research and Development Agreement (CRADA). Sorrento plans to initiate additional clinical studies to rapidly advance the drug.
“Sorrento’s drug development pipeline now includes an additional clinical stage program to go along with its late stage program Cynviloq™ and robust pipeline of fully human therapeutic antibodies,” said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. “Resiniferatoxin is a great fit with our mission to treat cancer patients with targeted and selective treatments. End-stage cancer pain is a particularly high unmet medical need and the early data with Resiniferatoxin are very encouraging.”
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento’s therapeutic focus is oncology, but it is also developing therapeutic products for inflammation, metabolic, and infectious diseases. Sorrento’s proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary ADCs as well as AfDCs combining its G-MAB® antibodies with anti-tumor agents.
SOURCE: Sorrento Therapeutics
Post Views: 229
